Skip to content
value.today

Aardvark Therapeutics, Inc.

AARD
$32 Mmarket cap on Oct 30, 2026
Compare
World rank
#22,888
Revenue
—
For year ending December-2025
Net income
$-58 M
SEC filing
Employees
40
As of February 28, 2026
SEC filing

Aardvark Therapeutics, Inc. in brief

Aardvark Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $32 M on 30 October 2026, which makes it the 22,888th largest listed company in the world and the 4,028th largest in the USA on this site. It employs about 40 people and Tien-Li Lee is its chief executive. Its shares trade under the symbol AARD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Aardvark Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the chemicals in food and participate in the gut-brain axis. Our research has shown that activating these receptors can induce the secretion of endogenous signaling molecules, including cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1).

From the company's annual report filed with the US SEC: read the report

Aardvark Therapeutics, Inc. timeline

2 events, 2019–2025
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 13 February 2025; shares registered for exchange trading on 10 February 2025.

Events of Aardvark Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$39 M$77 M$116 M$154 M

World rank over time

▼ down 6,564 places since 2026
2026-08-01: #16345#16,34520262026-10-08: #18533#18,53320262026-10-30: #22909#22,9092026

Rank in USA: #3,261 (Aug 2026) · #3,455 (Oct 2026) · #4,031 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.3×
Free cash flow yield
-172.2%
Net margin
—
Operating margin
—
Return on equity
-54.0%
Liabilities / assets
9.0%
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-21M—FY24Fiscal year ending Dec 2025: revenue —, net income $-58M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-63M$-58M—
Dec 2024——$-23M$-21M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-54M$0M$-54M$-2.93—
Dec 2024$-18M$0M$-18M$-5.15—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-9M—Dec ’24Three months to Mar 2025: revenue —, net income $-9M—Mar ’25Three months to Jun 2025: revenue —, net income $-14M—Jun ’25Three months to Sep 2025: revenue —, net income $-16M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-18M—Dec ’25Three months to Mar 2026: revenue —, net income $-22M—Mar ’26Three months to Jun 2026: revenue —, net income $-14M—Jun ’26Three months to Sep 2026: revenue —, net income $-19M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Aardvark Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-63 M
Net income
$-58 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$117 M
Total liabilities
$11 M
Total equity
$107 M

As of December-2025

Top 76 institutional investors in Aardvark Therapeutics, Inc.#

As of Sep 30, 2026
76 institutions held 9.5 M shares (about 43.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 37.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Aardvark Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Decheng Capital LLC3,917,2990 (0.00%)17.90%$21 MNov 13, 2026
2Laurion Capital Management LP1,034,4590 (0.00%)4.73%$5 MOct 30, 2026
3Citadel Advisors LLC975,028-308,138 (-24.01%)4.46%$5 MNov 16, 2026
4EcoR1 Capital, LLC720,028+323,834 (+81.74%)3.29%$4 MNov 16, 2026
5Vanguard Capital Management LLC557,926-4,951 (-0.88%)2.55%$3 MNov 13, 2026
6ExodusPoint Capital Management, LP316,427New1.45%$2 MNov 16, 2026
7BlackRock, Inc.194,620+7,575 (+4.05%)0.89%$1 MNov 13, 2026
8Geode Capital Management, LLC139,007-10,837 (-7.23%)0.64%$1 MNov 6, 2026
9Marshall Wace, LLP132,204+113,128 (+593.04%)0.60%$1 MNov 13, 2026
10Jacobs Levy Equity Management, Inc130,165New0.59%$1 MNov 16, 2026
11Two Sigma Investments, LP129,577+21,200 (+19.56%)0.59%$1 MNov 16, 2026
12AQR Capital Management LLC114,053-366,196 (-76.25%)0.52%$1 MNov 16, 2026
13Raymond James Financial Inc92,892+13,608 (+17.16%)0.42%$0 MNov 12, 2026
14Cantor Fitzgerald, L. P.91,682-141,482 (-60.68%)0.42%$0 MNov 16, 2026
15Velan Capital Investment Management LP85,868New0.39%$0 MNov 16, 2026
16Vanguard Fiduciary Trust Co75,1720 (0.00%)0.34%$0 MNov 13, 2026
17Jane Street Group, LLC68,636+46,172 (+205.54%)0.31%$0 MNov 12, 2026
18Millennium Management LLC62,454-7,494 (-10.71%)0.29%$0 MNov 16, 2026
19Susquehanna International Group, LLP60,976+36,951 (+153.80%)0.28%$0 MNov 16, 2026
20State Street Corp57,573-1,700 (-2.87%)0.26%$0 MNov 12, 2026
21J. Goldman & Co LP54,127+13,627 (+33.65%)0.25%$0 MNov 16, 2026
22Adage Capital Partners GP, L.L.C.50,000-250,000 (-83.33%)0.23%$0 MNov 16, 2026
23D. E. Shaw & Co., Inc.40,558New0.19%$0 MNov 16, 2026
24Simplex Trading, LLC37,538+21,621 (+135.84%)0.17%$0 MNov 4, 2026
25Point72 Asset Management, L.P.35,456+12,584 (+55.02%)0.16%$0 MNov 16, 2026
Show all 76: investors 26 to 76
Institutional investors 26 to 76 in Aardvark Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26XTX Topco Ltd35,246+15,358 (+77.22%)0.16%$0 MNov 16, 2026
27Northern Trust Corp28,0800 (0.00%)0.13%$0 MNov 16, 2026
28Barclays PLC25,792+23,533 (+1041.74%)0.12%$0 MNov 6, 2026
29Cresset Asset Management, LLC24,000-33 (-0.14%)0.11%$0 MNov 16, 2026
30Smith, Moore & Co.23,725+3,725 (+18.62%)0.11%$0 MNov 12, 2026
31Bridgeway Capital Management, LLC23,602-398 (-1.66%)0.11%$0 MNov 16, 2026
32Empowered Funds, LLC23,602New0.11%$0 MNov 13, 2026
33FMR LLC18,900-4 (-0.02%)0.09%$0 MNov 10, 2026
34Dimensional Fund Advisors LP17,710New0.08%$0 MNov 4, 2026
35Schonfeld Strategic Advisors LLC15,942New0.07%$0 MNov 16, 2026
36Verdad Advisers, LP14,953New0.07%$0 MNov 16, 2026
37Quadrature Capital Ltd12,271New0.06%$0 MNov 13, 2026
38Gsa Capital Partners LLP11,808New0.05%$0 MNov 16, 2026
39Goldman Sachs Group Inc10,465-1,776 (-14.51%)0.05%$0 MNov 16, 2026
40Trexquant Investment LP10,329New0.05%$0 MNov 16, 2026
41Ieq Capital, LLC10,294-28,088 (-73.18%)0.05%$0 MNov 10, 2026
42Abel Hall, LLC10,0660 (0.00%)0.05%$0 MOct 19, 2026
43BNP Paribas Financial Markets9,971+8,663 (+662.31%)0.05%$0 MNov 12, 2026
44Morgan Stanley7,429-22,748 (-75.38%)0.03%$0 MNov 13, 2026
45Steward Partners Investment Advisory, LLC6,930+2,780 (+66.99%)0.03%$0 MNov 13, 2026
46Vanguard Global Advisers, LLC5,8930 (0.00%)0.03%$0 MNov 13, 2026
47Arax Advisory Partners4,210-4,164 (-49.73%)0.02%$0 MNov 12, 2026
48China Universal Asset Management Co., Ltd.3,993+521 (+15.01%)0.02%$0 MOct 28, 2026
49Tower Research Capital LLC (TRC)2,991+490 (+19.59%)0.01%$0 MNov 16, 2026
50Jpmorgan Chase & Co1,630-154 (-8.63%)0.01%$0 MNov 12, 2026
51UBS Group AG1,436-34,203 (-95.97%)0.01%$0 MNov 10, 2026
52Russell Investments Group, Ltd.1,2390 (0.00%)0.01%$0 MNov 6, 2026
53Mirae Asset Global Investments Co., Ltd.1,118+142 (+14.55%)0.01%$0 MOct 29, 2026
54Group One Trading LLC1,074New0.00%$0 MNov 10, 2026
55Stone House Investment Management, LLC1,0000 (0.00%)0.00%$0 MOct 23, 2026
56Federated Hermes, Inc.6460 (0.00%)0.00%$0 MNov 12, 2026
57Citigroup Inc581-25,718 (-97.79%)0.00%$0 MNov 4, 2026
58GF Fund Management Co. LTD.492+40 (+8.85%)0.00%$0 MOct 26, 2026
59Hilton Head Capital Partners, LLC4340 (0.00%)0.00%$0 MOct 23, 2026
60GAMMA Investing LLC3880 (0.00%)0.00%$0 MOct 8, 2026
61Royal Bank Of Canada376+207 (+122.49%)0.00%$0 MNov 16, 2026
62PNC Financial Services Group, Inc.344-5 (-1.43%)0.00%$0 MNov 6, 2026
63EverSource Wealth Advisors, LLC286-488 (-63.05%)0.00%$0 MNov 4, 2026
64Allworth Financial LP181-632 (-77.74%)0.00%$0 MNov 17, 2026
65Essential Partners LLC160-349 (-68.57%)0.00%$0 MOct 14, 2026
66Nuveen, LLC147New0.00%$0 MNov 10, 2026
67Rialto Wealth Management, LLC84New0.00%$0 MNov 16, 2026
68Nisa Investment Advisors, LLC700 (0.00%)0.00%$0 MOct 20, 2026
69Harbour Investments, Inc.61+8 (+15.09%)0.00%$0 MNov 9, 2026
70Rothschild Investment LLC48-217 (-81.89%)0.00%$0 MNov 10, 2026
71True Wealth Design, LLC27-135 (-83.33%)0.00%$0 MOct 13, 2026
72IFP Advisors, Inc20-427 (-95.53%)0.00%$0 MOct 16, 2026
73Farther Finance Advisors, LLC17-136 (-88.89%)0.00%$0 MOct 8, 2026
74Transamerica Financial Advisors, LLC140 (0.00%)0.00%$0 MNov 12, 2026
75Fortitude Family Office, LLC11-45 (-80.36%)0.00%$0 MOct 14, 2026
76JPL Wealth Management, LLC1-6 (-85.71%)0.00%$0 MNov 13, 2026

Mutual funds holding Aardvark Therapeutics, Inc.#

29 funds hold shares worth $5 M (about 4.4% of the company). Since their previous reports 13 added shares and 41 sold, selling $3 M net.
Mutual funds holding Aardvark Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.408,670$2 M1.9%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.140,389$1 M0.64%<0.01%+6.7%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors89,124$1 M0.41%<0.01%−0.6%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC66,747$0 M0.30%<0.01%+1.5%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.64,981$0 M0.30%<0.01%+3.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors42,615$0 M0.19%0.02%+37%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC24,000$0 M0.11%0.09%−11%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC22,633$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.22,439$0 M0.10%0.06%+16%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC18,735$0 M0.09%<0.01%+5.2%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC15,483$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.8,867$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,980$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.4,951$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.6,719$0 M0.03%<0.01%+3.1%May 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company4,636$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC4,479$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.4,264$0 M0.02%<0.01%+4.9%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,679$0 M0.01%<0.01%+14%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC2,474$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC1,503$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,274$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,472$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION800$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC600$0 M<0.01%<0.01%+9.1%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC475$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC469$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC200$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC72$0 M<0.01%<0.01%+5.9%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Aardvark Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$145 K
2 purchases, 2 insiders
Sold, 12 months
$395 K
2 sales, 1 insider
Net, 12 months
-$250 K
open market only
Insiders on file
7
since
$23.4 M-$395 K$0Feb 2025: bought $23.4 M (5 trades), sold $0 (0 trades)Feb 25Sep 2025: bought $306 K (6 trades), sold $0 (0 trades)SepDec 2025: bought $145 K (2 trades), sold $0 (0 trades)DecSep 2026: bought $0 (0 trades), sold $395 K (2 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Aardvark Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Nelson SunSee RemarksSell10b5-1 plan-62,000$5.180$321 K35,475Form 4
filed Nelson SunSee RemarksSell10b5-1 plan-14,754$5.000$74 K97,475Form 4
filed Tien-Li LeeChief Executive Officer, Director, 10% ownerBuy+7,000$14.49$101 K1.55 MForm 4
filed Nelson SunChief Financial OfficerBuy+3,000$14.40$43 K108,484Form 4
filed Bryan JonesChief Operating OfficerOption exercise+1,250$4.240$5 K1,250Form 4
filed Tien-Li LeeChief Executive Officer, Director, 10% ownerOption exercise+1,229$4.240$5 K1.54 MForm 4
filed Tien-Li LeeChief Executive Officer, Director, 10% ownerBuy+6,500$9.510$62 K1.54 MForm 4
filed Tien-Li LeeChief Executive Officer, Director, 10% ownerBuy+3,500$9.940$35 K1.54 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Aardvark Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.0 M
4.8% of shares · 1 days to cover
Reg SHO threshold list
7 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $16.00, raising $94.2M · IPO calendar

Stock splits: 1-for-8.47 reverse split in the period to

Trading halts

  • 2026-10-23 13:51 UTC, code LUDP, resumed 13:56 UTC
  • 2026-10-23 13:45 UTC, code LUDP, resumed 13:50 UTC
  • 2026-10-23 13:39 UTC, code LUDP, resumed 13:44 UTC
  • 2026-10-22 20:01 UTC, code T3, resumed 20:35 UTC
  • 2026-05-15 13:36 UTC, code LUDP, resumed 13:41 UTC

Fails to deliver

  • : 176,079 shares at $1.44
  • : 302,948 shares at $1.51
  • : 507,252 shares at $1.30
  • : 501,028 shares at $1.08
  • : 306,616 shares at $1.39

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Aardvark Therapeutics, Inc. scorecard#

Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-172.2%Free cash flow is -172.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.93 vs -5.15Diluted EPS -2.93 in fiscal 2025 against -5.15 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$58 MNet income -$58 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-221.5%-221.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities10.6×Current ratio 10.61 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year391.1%Diluted shares up 391.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Aardvark Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Aardvark Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Revenue0—
Research and development4917
General and administrative145.3
Operating expenses6323
Operating income−63−23
Interest and finance income5.12.4
Other non-operating income (expense)5.12.2
Income tax00
Net income attributable to shareholders−58−21
Earnings per share, basic-2.93-5.15
Earnings per share, diluted-2.93-5.15
Shares, weighted average (basic)204.0
Shares, weighted average (diluted)204.0
Balance sheet
Cash and cash equivalents4762
Short-term investments6312
Other current assets1.90.5
Current assets11274
Right-of-use (leased) assets0.40.7
Total assets11778
Accounts payable2.12.3
Current liabilities114.9
Lease liabilities (non-current)00.4
Total liabilities115.4
Retained earnings−116−58
Shareholders' equity107−55
Total liabilities and equity11778
Shares outstanding224.1
Cash-flow statement
Depreciation and amortization0.00.0
Share-based compensation3.90.4
Cash from operating activities−54−18
Capital expenditure−0.1−0.1
Cash from investing activities−50−12
Shares issued0.20
Cash from financing activities8982
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Aardvark Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7

Aardvark Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 8, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Aardvark Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$85 MNo. 3$50 to $250 million31equitySEC
May 2021$9 MNo. 2$2 to $10 million8equitySEC
May 2019$9 MNo. 1$2 to $10 million12equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Aardvark Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $120 K a year.

Certified, FY2026
1
#1,951 among companies on value.today
Worker positions
1
Median wage offered
$120 K
a year, full-time
Applications filed
1
Aardvark Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Sr. Project ManagerProject Management Specialists1$120 K

Where: San Diego, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aardvark Therapeutics Inc.

How Aardvark Therapeutics, Inc. compares in Biotechnology

  • Market cap$32 M · higher than 22% of 726
  • Price / book0.3× · lower than 97% of 534
  • FCF yield-172.2% · higher than 2% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Aardvark Therapeutics, Inc.🇺🇸$32 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 28, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Aardvark Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Aardvark Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Aardvark Therapeutics, Inc.? Suggest a correction